Please login to the form below
medicines value
This page shows the latest medicines value news and features for those working in and with pharma, biotech and healthcare.
Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough
cost and value of the drug, which has a list price of £104, 000 ($136, 000) per patient per year. ... to capture the full value of specialist medicines for small populations.
Latest news
-
Greater Manchester backs move to outcome-based payment
able to access new and innovative medicines as early as possible and delivering better value for money.”. ... Outcome-based pricing could help the NHS get better value from new medicines and help our members better understand how treatments are
-
Vertex an “extreme outlier” in pricing and behaviour, says NHS England
However, Vertex rejected this offer, saying it “fails to adequately reflect the value of our current and future medicines and the number of patients that will be treated with these medicines". ... Other pharmaceutical companies are working
-
NICE rejects Novartis migraine treatment Aimovig
Ahmad adds: “NICE does not consider impact of diseases on broader society when evaluating the cost-effectiveness of medicines. ... We believe this fails to capture the true value of medicines like Aimovig.
-
NHS Long-term Plan welcomed – but warnings on staff and overpromising
UK pharma industry response. The new Long-term Plan coincides with the launch of a new five year Voluntary Pricing and Access Scheme (VPAS) covering branded medicines in the UK. ... He also hailed the introduction of the VPAS, saying it “should see the
-
FDA fast tracks Novartis’ SMA gene therapy
Novartis and AveXis are proud to lead the way toward a modern healthcare system built on the tremendous value of truly innovative and transformative medicines that could bend the curve of ... life. We are committed to flexibly partnering with healthcare
More from news
Approximately 2 fully matching, plus 124 partially matching documents found.
Latest Intelligence
-
The first, my last, my everything
This growing empowerment arguably has its biggest impact in the arena of high-value medicines. ... The patient voice is increasingly being used to influence payers and encourage them to support high-value medicines.
-
The Orkambi blame game
on the cost and value of the drug, which has a list price of £104, 000 ($136, 000) per patient per year. ... is to capture the full value of specialist medicines for small populations.
-
#OrkambiNow?
per patient per year price – comparable to the cost of older and less effective CF medicines such as Pulmozyme. ... New models urgently needed. It’s widely acknowledged that healthcare systems and the industry need to converge around new models,
-
The UK’s new five-year pricing agreement
Value assessment. More and faster NICE appraisals for new medicines including speeding up the appraisal of non-cancer medicines to be in line with cancer medicine appraisals – cost-effective new medicines ... Commercial arrangements. Opportunities for
-
Deal Watch October 2018
Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for. ... Sandoz’s US business has retained its biosimilars, value‐added medicines and complex generics, including the ophthalmology products.
More from intelligence
Approximately 1 fully matching, plus 43 partially matching documents found.
Latest appointments
-
Redx poaches AstraZeneca senior executive
grow this company into a very excising and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders.".
-
Sanofi appoints Dr Yong-Jun Liu as head of research
April. In his new role, Dr Liu will be responsible for all of the Paris-based pharmaceutical company's research and will be tasked with delivering innovative and high-value medicines.
-
ABPI Scotland appoints Sandra Auld as director
the access to and use of new and innovative medicines for Scottish patients. . ... The ABPI Scotland team is fully committed to working with all of our stakeholders to support a common understanding and appreciation of the life-saving and life-enhancing
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
NHS medicines optimisation milestone
by 2020/21 if the NHS embraces the use of best value biological medicines in a proactive, systematic and safe way’. ... needs to redefine its value proposition and move the focus away from direct medicines costs to demonstrating how savings can be made
-
How to measure health behaviour change programmes
The value outcome of medicines is still largely measured against healthcare systems or general societal outcomes. ... But the ways in which we measure patient benefits and value needs to be equally creative. .
-
How will the NHS’s new medicines savings drive affect pharma?
value medicines that can be easily bought over-the-counter, such as antihistamines and sun cream. . ... In conclusion, the need for pharma to prove the value of its products has never been greater.
-
Using new technologies to capture the patient's voice
Regulators, payers and medical professionals recognise the patient voice as the missing link in maximising value from the global healthcare bill. ... world evidence that enables them to continue appraising the safety, efficacy and value of medicines over
-
Packer Forbes collaborates with NHS Expert to strengthen growing team
With today’s emphasis on economic as well as clinical value, it recognises access barriers to medicines as a key challenge and works to uncover insightful understanding of the issues in
More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.
Featured jobs
-
Director – Healthcare PR
-
Salary TBC
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Competitive salary and benefits
-
Senior Medical Writer
-
Salary TBC
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
Subscribe to our email news alerts
- With Spiriva under pressure, Boehringer moves to bolster pipeline
- Genfit claims FDA breakthrough status for liver disease drug
- Mereo’s shareholders back OncoMed takeover
- Lucid Group announces the appointment of new CFO
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
PMHub
Swordfish Advertising
At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
